Chaim Hurvitz - Oct 21, 2022 Form 4/A - Amendment Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Role
Director
Signature
/s/ Chaim Hurvitz
Stock symbol
NRXP
Transactions as of
Oct 21, 2022
Transactions value $
$514,905
Form type
4/A - Amendment
Date filed
11/23/2022, 03:09 PM
Date Of Original Report
Nov 21, 2022
Previous filing
Jun 10, 2021
Next filing
Sep 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRXP Common Stock Purchase $285K +288K $0.99 288K Nov 16, 2022 Direct F1
transaction NRXP Common Stock Purchase $186K +172K +59.68% $1.08 460K Nov 17, 2022 Direct F2
transaction NRXP Common Stock Purchase $44.4K +40.4K +8.79% $1.10 500K Nov 18, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.00 to $0.93. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
F2 The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.01. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
F3 The original Form 4 disclosed that the price reported in Column 4 is a weighted average price. This Form 4/A is being filed to amend such information. The shares were purchased in a single transaction at $1.10.